PMS and PMDD: Recognition and Relief

Premenstrual syndrome includes physical and emotional symptoms in the luteal phase that resolve shortly after menstruation begins. Tracking across two or more cycles clarifies patterns.

Premenstrual dysphoric disorder (PMDD) involves severe mood symptoms—depression, irritability, or anxiety—that impair relationships and work. It is a medical diagnosis with effective therapies.

SSRIs, hormonal strategies, lifestyle changes, and therapy reduce symptom burden. Calcium and exercise show modest benefit for some individuals with PMS.

Dismissing cyclical mood disruption as 'just hormones' delays care. Symptom diaries empower accurate diagnosis.

Telling PMS and PMDD apart

Premenstrual syndrome (PMS) brings physical and emotional symptoms in the days before a period that ease once it begins. Premenstrual dysphoric disorder (PMDD) is a more severe form in which mood symptoms—marked irritability, depression, or anxiety—significantly disrupt life. Tracking symptoms across two or three cycles helps distinguish the two and guides treatment.

What helps

Regular exercise, sleep, reducing caffeine and alcohol, and stress management ease milder symptoms. For PMDD, evidence supports certain antidepressants and hormonal approaches, so a clinician's input is valuable. Symptom charting is not just diagnostic—it also helps you and your provider judge whether a treatment is working.

What Distinguishes PMS From PMDD — and From Normal Cyclical Changes

Mild mood changes, breast tenderness, and bloating in the week before menstruation are experienced by up to 90 % of people with cycles and represent a normal hormonal variation. Premenstrual syndrome (PMS) is diagnosed when these symptoms are moderate to severe and consistently impair functioning. Premenstrual dysphoric disorder (PMDD) represents the severe end of the spectrum: a recognised psychiatric and gynaecological condition in which emotional symptoms — particularly marked irritability, anger, anxiety, or depressed mood — are so intense that work, relationships, and daily activities are significantly disrupted in the luteal phase every cycle.

The diagnostic difference between PMS and PMDD is primarily one of severity and the prominence of psychological symptoms. PMDD additionally requires prospective symptom tracking over at least two consecutive cycles to confirm that symptoms are truly cyclical — peaking in the week before menstruation and resolving within a few days of onset. This prospective confirmation is essential because retrospective reporting frequently misidentifies non-cyclical mood disorders as PMDD, and the treatments are different.

The Biology of Sensitivity: Why Some People Are More Affected

PMS and PMDD are not caused by abnormal hormone levels. Research comparing women with PMDD and controls has consistently found that serum oestrogen and progesterone levels are statistically similar. The key difference lies in brain sensitivity to normal luteal-phase hormonal fluctuations, particularly to neurosteroids derived from progesterone. Allopregnanolone, a progesterone metabolite that normally acts as a GABA-A receptor modulator (producing a calming effect), appears to paradoxically trigger anxiety and irritability in people with PMDD due to differences in receptor subunit composition.

Genetic studies have identified differentially expressed genes in the lymphocytes of women with PMDD related to ESC/E(Z) transcriptional regulatory complex — a biological pathway involved in cellular response to sex hormones. This suggests PMDD is a disorder of how cells process hormonal signals, not a disorder of hormone levels themselves. This distinction has practical implications: it explains why simply measuring oestrogen or progesterone levels is not diagnostically useful for PMS or PMDD.

Prospective Symptom Tracking: How to Do It Properly

Using a validated tool such as the Daily Record of Severity of Problems (DRSP) or the Premenstrual Symptoms Screening Tool (PSST) provides a standardised, clinician-recognisable record. Rate each symptom daily from the first day of one period to the first day of the next — not from memory at the end of the cycle, as retrospective recall is consistently inaccurate. Record your cycle day alongside each entry. Two full cycles of daily ratings are the minimum needed to establish a clear luteal-phase pattern.

Look for the pattern of symptoms being absent or minimal in the follicular phase (days 1–10 approximately), worsening from roughly day 14–16 onward, peaking in the few days before menstruation, and clearing within two to four days of menstrual onset. If symptoms are present throughout the cycle with only a mild pre-menstrual worsening, an underlying mood disorder — depression, anxiety, or ADHD, all of which have premenstrual exacerbations — is more likely and warrants primary treatment.

Evidence-Based First-Line Treatments for PMS and PMDD

For PMDD, SSRIs are a first-line pharmacological treatment with the strongest evidence base. Uniquely for PMDD, SSRIs can be used luteal-phase only — taken from ovulation until menstruation — and achieve comparable efficacy to continuous dosing for most people. This is possible because the mechanism of action in PMDD appears to involve rapid modulation of neurosteroid sensitivity rather than the gradual receptor changes that require continuous dosing for depression. Commonly used SSRIs include fluoxetine, sertraline, and escitalopram; all show robust efficacy.

The combined oral contraceptive pill containing ethinylestradiol and drospirenone in a 24-active/4-placebo regimen (eg Yaz) is the only oral contraceptive with regulatory approval for PMDD in several countries. It works by suppressing ovulation and thereby preventing the hormonal fluctuations that trigger symptoms. Continuous use without a hormone-free interval may provide additional benefit by eliminating the small oestrogen drop during the pill-free week that can itself trigger symptoms in sensitive individuals.

Lifestyle Modifications With a Genuine Evidence Base

Aerobic exercise performed consistently throughout the month — not just during the luteal phase — reduces overall PMS severity. A meta-analysis of randomised controlled trials found exercise significantly reduces both physical and psychological PMS symptoms, likely through effects on serotonin, beta-endorphin release, and stress reactivity. Aim for 150 minutes of moderate-intensity aerobic activity per week. Resistance training has additive benefits and is particularly helpful for the fatigue and lethargy component.

Calcium supplementation (1200 mg daily) has been shown in multiple trials to reduce PMS symptom scores by approximately 48 % compared to placebo — one of the most robust dietary supplement findings in this field. Vitamin B6 (pyridoxine) at doses of 50–100 mg daily has modest evidence for mood-related symptoms. Magnesium glycinate at 200–400 mg in the luteal phase shows benefit for bloating, breast tenderness, and mood. Reducing caffeine, alcohol, and high-sodium foods in the luteal phase addresses specific symptoms including anxiety, fluid retention, and sleep disruption.

When Lifestyle and First-Line Treatments Fail

If SSRIs and the combined pill are ineffective or poorly tolerated, second-line options include other progestogen-dominant contraceptives, GnRH analogues with add-back hormone therapy (which induce a temporary medically managed menopause, eliminating cyclical hormonal fluctuation), or the antiandrogen/progestin spironolactone, which has good evidence for physical symptoms including bloating and breast pain. Psychological approaches including CBT tailored to PMDD show meaningful benefit and can be used alongside any pharmacological treatment.

Surgical removal of the ovaries (oophorectomy) is an irreversible last resort for truly refractory severe PMDD and is only considered after extensive conservative treatment failure in people who have completed their families and are in significant psychological distress. Because oophorectomy triggers surgical menopause, subsequent hormone therapy planning is essential. This decision requires specialist gynaecological and psychiatric input and considerable personal reflection.

Frequently Asked Questions

Q: Can PMDD get worse over time? A: Yes, PMDD often intensifies during perimenopause when hormonal fluctuations become more extreme. Some people first experience PMDD after a hormonal event such as pregnancy, stopping the pill, or a particularly stressful life period. Symptoms can remit permanently at menopause once hormonal cycling ceases, which itself helps confirm the diagnosis retrospectively.

Q: Is PMDD a mental health condition or a gynaecological one? A: It is recognised as both. PMDD appears in the DSM-5 as a depressive disorder and is addressed in gynaecological guidelines as a cyclical hormonal condition. This dual classification reflects its nature: a disorder of hormonal sensitivity with predominantly psychological symptoms. Treatment typically involves collaboration between reproductive health clinicians and mental health professionals.

Q: Will SSRIs taken in the luteal phase cause withdrawal symptoms when stopped each month? A: Short-course luteal-phase SSRIs at low doses do not typically cause significant discontinuation symptoms in most people. However, some individuals notice dizziness or flu-like symptoms when stopping, particularly with shorter half-life medications like paroxetine or fluvoxamine. Using a longer half-life SSRI such as fluoxetine largely eliminates this concern. Discuss the specific approach with a prescribing clinician.

Q: How do I explain PMDD to people around me? A: Explaining that PMDD is a recognised medical condition in which a sensitive brain reaction to normal hormonal changes causes debilitating monthly symptoms — rather than 'being moody' — is a useful starting point. Sharing a clinical resource such as a patient leaflet from a gynaecological or psychiatric professional body can help validate the condition for people unfamiliar with it. Asking for specific, practical support such as reduced commitments or extra patience during the luteal phase is a constructive approach.